Table 1 Patient characteristics
All patients | Less than 2.8 years since pregnancy | Greater than 2.8 years since pregnancy | |
|---|---|---|---|
Number | 241 | 200 | 41 |
Median age | 30 (range 17–61) | 33 (range 17–54) | 35 (range 22–61) |
Median Prognostic score (WHO). | 11 (range 8–32) | 11 (range 8–32) | 14 (range 9–32) |
Median Prognostic score (FIGO). | 8 (range 4–20) | 8 (range 4–18) | 9 (range 5–20) |
Median follow-up | 11.7 years | 11.9 years | 6.2 years |
Range 0.1–23.8 | Range 0.9–23.8 | Range 0.1–23.8 | |
Median HCG at presentation | 190 000 | 200 000 | 72 000 |
300–3.4 million | 300–3.3million | 450–3.4million | |
Chemotherapy regimens | |||
EMA/CO | 206 (85%) | 174 (87%) | 32 (80%) |
EP/EMA | 14 (6%) | 9 (5%) | 5 (12%) |
EMA/CNS | 17 (7%) | 14 (7%) | 3 (7%) |
Other | 4 (1%) | 3 (2%) | 1 (1%) |
Causal pregnancy | |||
Term | 125 (52%) | 96 (48%) | 29 (70%) |
Abortion/unknown | 37 (15%) | 32 (16%) | 6 (15%) |
Molar | 79 (33%) | 73 (35%) | 6 (15%) |
Sites of metastasis | |||
Pulmonary | 98 (41%) | 77 (39%) | 21 (51%) |
Extrapulmonary | 38 (16%) | 30 (15%) | 8 (20%) |
Both | 26 (10%) | 18 (9%) | 8 (20%) |
Deaths | 27 (11%) | 12 (6%) | 15 (37%) |
Cancer-related deaths | 23 (10%) | 10 (5%) | 13 (32%) |
5-year survival | 87.4% | 94.0% | 62.0% |
95% CI: (77.8–96.8) | 95% CI: (91.3–97.0%) | (95% CI: 47.2–76.8%) | |
